News

Citi Adjusts Altria's Price Target Amid Market Challenges

Citi Adjusts Altria's Price Target Amid Market Challenges

Citi Adjusts Altria's Price Target Amid Market Challenges

Citi has made an update regarding Altria Group Inc (NYSE:MO), one of the foremost companies in the tobacco industry. The financial services firm has raised its price target for Altria's stock from $44.50 to $48.00. This adjustment reflects a cautious approach, as Citi has decided to keep a Neutral rating on the shares due to ongoing challenges in the market.

Current Market Conditions and Forecasts

The analysts at Citi have pointed out that the challenging environment for combustible products is likely to impact Altria's delivery figures for the upcoming third quarter. Consequently, they have adjusted their estimates for both the third quarter and the full fiscal year, placing these forecasts lower than the overall market consensus.

Earnings Projection

Citi's projections suggest that Altria’s earnings per share (EPS) for the full year in 2024 will sit at around $5.09, which is on the lower end of the company's guidance. Despite these forecasts, there is an expectation that Altria's management will continue to reaffirm their full-year guidance metrics, suggesting a level of confidence moving forward.

Stock Performance Insights

Over the course of the third quarter, Altria's stock has seen favorable performance. Nonetheless, analysts suggest that if there is no significant movement towards defensive stocks, the share price may experience a downward trend in the weeks ahead. This highlights the volatile nature of the current market.

Additional Analyst Perspectives

In a related note, BofA Securities has revised their price target for Altria from $52 up to $57 while maintaining a neutral stance. This target revision is based on a valuation of 10.7 times the estimated EPS for 2025, which remains predicted at $5.32. Stifel is also optimistic, having reaffirmed their buy rating on Altria, emphasizing both strong dividend payments and a steady outlook for EPS growth.

Dividend Growth Strategy

Recently, Altria took a significant step by increasing its quarterly dividend by 4.1%, raising it from $0.98 per share to $1.02. This move aligns with the company’s strategy aimed at achieving mid-single-digit growth in dividends per share annually until at least 2028. It's worth noting that the company reported a stable adjusted diluted EPS for the second quarter of 2024, despite facing a small decline during the first half of the year.

Financial Metrics and Valuation

Looking deeper into the financial metrics and market performance of Altria Group, recent data reveals a favorable price-to-earnings (P/E) ratio of 8.62, significantly lower than many competitors in the consumer staples sector. Such a low valuation indicates that Altria could potentially be undervalued when considering its earnings prospects.

Profitability and Dividend Appeal

Despite the industry challenges highlighted by Citi, Altria's profitability remains strong, with a gross profit margin of 69.56% reported for the past twelve months as of Q2 2024. This level of profitability positions the company well to endure market pressures.

Moreover, Altria's dividend yield stands out at 8.17%, which can be particularly appealing to investors in the current financial climate. Over the past twelve months, a notable dividend growth of 8.51% has further reinforced the company's commitment to returning value to shareholders, supporting stock performance even in light of anticipated short-term pressures.

Frequently Asked Questions

What did Citi change regarding Altria's stock outlook?

Citi raised the price target for Altria's stock from $44.50 to $48.00 but maintained a Neutral rating amidst ongoing challenges.

What challenges is Altria currently facing?

Altria is facing challenges in the combustible products market, which may impact their delivery numbers and overall performance.

What is the projected EPS for Altria in 2024?

Citi projects that Altria's earnings per share (EPS) will be around $5.09 for the full fiscal year of 2024.

How has Altria's stock performed recently?

Altria's stock has shown strong performance throughout the third quarter, although there may be potential downward trends if defensive stocks do not attract more investors.

What has Altria done regarding its dividend payments?

Altria increased its quarterly dividend by 4.1%, from $0.98 to $1.02 per share, supporting a strategy for consistent annual growth until 2028.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Monib Zirvi's Dermatology Excellence Honored in 2026

Updated Category News Views 6

Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...

Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies

Updated Category News Views 3

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Continue Reading
RTI's $14M Boost: A Game-Changer for Tech Innovators

Updated Category News Views 3

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Continue Reading
AI Trust in Finance: Survey Reveals Market Impact

Updated Category News Views 2

Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....

Continue Reading
Cove Capital Secures $9.96M for Debt-Free Logistics DST

Updated Category News Views 5

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Continue Reading
Maurices Strengthens Position with Key Refinancing Deal

Updated Category News Views 5

Maurices' Bold Financial Maneuver When a retailer like Maurices, with its near-century-long history, decides to play in the financial arena, it sure makes my ears perk up. This Duluth-based women's fashion retailer isn't just dipping its toes in—it's executing a full-blown refinancing blitzkrieg and coming out stronger. Announcing the completion of its refinancing plan...

Continue Reading
Deadline Looms for EquipmentShare Investors' Legal Action

Updated Category News Views 2

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

Continue Reading
Cannabis Industry Pushes for Robust Financial Services

Updated Category News Views 3

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 2

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 7

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading

Top 5 Most Recently Viewed Articles

PIMCO Canada Details Mergers for Enhanced Investment Funds

Updated Category News Views 103

Understanding the Proposed Mergers by PIMCO Canada PIMCO Canada Corp. recently announced exciting plans regarding the mergers of several closed-end funds. The proposed mergers, which involve the PIMCO Tactical Income Fund, PIMCO Tactical Income Opportunities Fund, and PIMCO Multi-Sector Income Fund, aim to create a new consolidated fund called the PIMCO Monthly Enhanced...

Continue Reading
Sodium Reduction Market: $11.5B by 2036, Wild Ride Ahead

Updated Category News Views 4

Riding the Sodium Reduction Wave Alright, folks, let's chew the fat about this sodium reduction ingredient market. It’s looking like it's gonna swell from $6.3 billion in 2026 to a whopping $11.5 billion by 2036. That's a steady 6.2% annual clip. We've got health-conscious consumers and government regulations kicking the demand for sodium reduction solutions into high...

Continue Reading
Evercore ISI Upgrades Microsoft Stock with Strong Fundamentals

Updated Category News Views 45

Evercore ISI Maintains Positive Outlook on Microsoft Stock Recently, Evercore ISI expressed confidence in Microsoft Corporation (NASDAQ: MSFT) by retaining its Outperform rating and an ambitious price target of $500.00. The firm stands by the company’s robust fundamentals, even amidst a slight slowdown in stock performance compared to the S&P 500 index. Understanding...

Continue Reading
Hess CEO Predicts Stronger Oil Market and Guyana Growth

Updated Category News Views 176

Hess CEO Shares Positive Outlook for Oil Demand John Hess, the CEO of Hess Corporation (NYSE: HES), recently expressed an optimistic perspective on the oil market during his presentation at a leading energy conference. He believes that the market is moving towards a balance rather than facing oversupply, despite concerns regarding demand from certain regions and...

Continue Reading
CorMedix Inc. Reports Strong Q3 Growth Fueled by DefenCath

Updated Category News Views 130

CorMedix Inc. Shows Promising Financial Growth in Q3 In a recent financial results conference call, CorMedix Inc. (NYSE American: CRMD) unveiled a significant achievement in the third quarter of 2024, with net revenue soaring to $11.5 million. This growth was primarily fueled by the successful launch and ongoing rollout of its flagship product, DefenCath. The company has...

Continue Reading